Paper Details
- Home
- Paper Details
Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
Author: LongXiaoqing, WangJisheng, ZhaoDehua
Original Abstract of the Article :
Poly (ADP-ribose) polymerase (PARP) inhibitors are small-molecule inhibitors of PARP enzymes (including PARP1, PARP2, and PARP3) that exhibit activity against tumor cells with defects in DNA repair. In recent years, five PARP inhibitors, olaparib, niraparib, rucaparib, talazoparib and veliparib, hav...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673935/
データ提供:米国国立医学図書館(NLM)
PARP Inhibitors: Navigating the Desert of Hepatic and Renal Impairment
The field of oncology is constantly evolving, with new treatments emerging to combat the complexities of cancer. One such advancement is the development of PARP inhibitors, a class of drugs that target specific enzymes involved in DNA repair, disrupting the growth of tumor cells. This research explores the intricacies of using these inhibitors in patients with impaired liver or kidney function.
This study acts as a guide, providing insights into the pharmacokinetic properties of PARP inhibitors and their interactions with the liver and kidneys. The authors analyzed the existing data, meticulously navigating through the desert of research, to provide clinicians with practical recommendations for managing patients with hepatic or renal impairment.
Dose Adjustments: A Vital Tool for Navigating the Terrain
The researchers found that the pharmacokinetics of PARP inhibitors can be significantly affected by liver and kidney function. This necessitates careful dose adjustments to ensure optimal treatment while minimizing adverse effects. These findings are particularly relevant for clinicians who treat cancer patients with pre-existing medical conditions.
Navigating the Desert of Individual Needs
The research emphasizes the importance of individualizing treatment strategies. Each patient presents a unique set of challenges, and understanding how liver and kidney function impacts medication effectiveness is crucial. This research serves as a valuable resource for clinicians, guiding them through the intricate landscape of PARP inhibitor therapy.
Dr.Camel's Conclusion
This study is a testament to the ongoing quest for better cancer treatments. It highlights the importance of individualized care, recognizing that each patient's journey is unique. As we continue to explore the desert of cancer research, understanding how medications interact with the body is critical to ensuring safe and effective treatment.
Date :
- Date Completed 2022-11-22
- Date Revised 2022-11-22
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.